CMIC HOLDINGS Co., Ltd. vs uBriGene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/cmicgroup/ubrigene

Category	CMIC HOLDINGS Co., Ltd.	uBriGene
Listed site	both	both
Summary	CMIC HOLDINGS is a Japanese healthcare group whose Pharmaceutical Solutions cover consulting, non-clinical CRO, CRO, CDMO, SMO and CSO services. The group says it supports pharmaceutical companies across the value chain from non-clinical stages through post-marketing.	uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.
Services	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy Clinical Trial Services	Analytical Method Development & Validation US FDA Regulatory Strategy EU EMA Regulatory Strategy China NMPA Regulatory Strategy Translational Research
Modalities	Data not yet provided.	mRNA Cell Therapy Gene Therapy AAV / Viral Vector Platform
Indications	Data not yet provided.	Oncology
Locations	Data not yet provided.	Headquarters, Maryland, Maryland, USA Boston, Boston, Massachusetts, USA Worcester, Worcester, Massachusetts, USA
Certifications	Data not yet provided.	FDA · Identifier: 20+ INDs filed and accepted EMA · Identifier: 20+ INDs filed and accepted NMPA · Identifier: 20+ INDs filed and accepted
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.